Literature DB >> 8316220

Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA.

R Honchel1, I A Aksoy, C Szumlanski, T C Wood, D M Otterness, E D Wieben, R M Weinshilboum.   

Abstract

Thiopurine methyltransferase (TPMT) catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine. Levels of TPMT activity in human tissue are controlled by a common genetic polymorphism that is an important factor responsible for individual variation in thiopurine drug toxicity and therapeutic efficacy. Our goal was to purify, to obtain a partial amino acid sequence for, and to clone and express cDNA for human TPMT as a first step in determining the molecular basis for this genetic polymorphism. Human kidney TPMT was purified, the protein was subjected to limited proteolysis, and amino acid sequence information was obtained from the resultant peptide fragments. Primers based on the amino acid sequence information were used to amplify a unique sequence from human liver cDNA by use of the polymerase chain reaction. Because TPMT has been reported to be present in the colon, T84 human colon carcinoma cells were studied and were found to express TPMT activity with biochemical properties similar to those of the human kidney and liver enzymes. Oligonucleotide probes based on the human kidney TPMT amino acid sequence were then used to screen a T84 human colon carcinoma cell cDNA library. A 2.7-kilobase cDNA clone was isolated that contained an open reading frame of 735 nucleotides, which encoded a protein of 245 amino acids. The deduced amino acid sequence of the encoded protein included one 24- and two separate 12-amino acid sequences identical to those obtained by sequencing proteolytic fragments of purified human kidney TPMT. Transcripts were made in vitro from the open reading frame of the cDNA clone. These transcripts were translated in a rabbit reticulocyte lysate system, and the resulting translation product comigrated with human kidney TPMT in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The T84 cell cDNA clone, truncated within the 3' untranslated region at an Sstl restriction site, was then used to create an expression construct with the eukaryotic expression vector P91023(B), and this construct was used to transfect COS-1 cells. The transfected cells expressed a high level of TPMT enzymatic activity, and this activity displayed a pattern of inhibition by TPMT inhibitors identical to that of human kidney and T84 human colon carcinoma cell TPMT. Cloning of cDNA for this important drug-metabolizing enzyme may make it possible to define the molecular basis of the TPMT genetic polymorphism in humans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8316220

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  18 in total

Review 1.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 2.  Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase.

Authors:  Richard M Weinshilboum
Journal:  Cell Mol Neurobiol       Date:  2006-06-29       Impact factor: 5.046

3.  Phenotyping and genotyping studies of thiopurine S-methyltransferase in Kazaks.

Authors:  Hong Wei; Shufeng Zhou; Chengrong Li; Jianping Zhang; Jueheng Wu; Min Huang
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

4.  Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity.

Authors:  H L Tai; E Y Krynetski; E G Schuetz; Y Yanishevski; W E Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

5.  Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity.

Authors:  D M Otterness; C L Szumlanski; T C Wood; R M Weinshilboum
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

Review 6.  Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm.

Authors:  E Y Krynetski; W E Evans
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

7.  Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine.

Authors:  C L Szumlanski; R M Weinshilboum
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

8.  Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians.

Authors:  H L Tai; E Y Krynetski; C R Yates; T Loennechen; M Y Fessing; N F Krynetskaia; W E Evans
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

9.  Thiopurine S-methyltransferase pharmacogenetics: functional characterization of a novel rapidly degraded variant allozyme.

Authors:  Qiping Feng; Suda Vannaprasaht; Yi Peng; Susothorn Angsuthum; Yingyos Avihingsanon; Vivien C Yee; Wichittra Tassaneeyakul; Richard M Weinshilboum
Journal:  Biochem Pharmacol       Date:  2009-11-27       Impact factor: 5.858

10.  Human S-adenosylhomocysteine hydrolase: common gene sequence variation and functional genomic characterization.

Authors:  Qiping Feng; Mani Keshtgarpour; Linda L Pelleymounter; Irene Moon; Krishna R Kalari; Bruce W Eckloff; Eric D Wieben; Richard M Weinshilboum
Journal:  J Neurochem       Date:  2009-07-08       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.